RetouraDSM
active tuberculosis drug-safety monitoring and management
AE
adverse event
AIDS
acquired immunodeficiency syndrome
ALT
alanine aminotransferase
aOR
adjusted odds ratio
ART
antiretroviral therapy
ARV
antiretroviral
AST
aspartate aminotransferase
AUC
area under the curve
BDLC
a regimen of bedaquiline, delamanid, linezolid and clofazimine
BDLLfxC
a regimen of bedaquiline, delamanid, linezolid, levofloxacin and clofazimine
BLLfxCZ
a regimen of bedaquiline, linezolid, levofloxacin, clofazimine and pyrazinamide
BLMZ
a regimen of bedaquiline, linezolid, moxifloxacin and pyrazinamide
BMI
body mass index
BPaL
a regimen of bedaquiline, pretomanid and linezolid
BPaLC
a regimen of bedaquiline, pretomanid, linezolid and clofazimine
BPaLM
a regimen of bedaquiline, pretomanid, linezolid and moxifloxacin
CB
clinical breakpoint
CC
critical concentration
CI
confidence interval
CLD
chronic liver disease
CNS
central nervous system
CSF
cerebrospinal fluid
CRF
chronic renal failure
CTP
Child–Turcotte–Pugh
CXR
chest radiography
DAA
direct-acting antiviral
DDI
drug–drug interaction
DRS
drug-resistance surveillance
DR-TB
drug-resistant tuberculosis
DS-TB
drug-susceptible tuberculosis
DST
drug susceptibility testing
ECG
electrocardiography
EMM
event monitoring device for medication support
FDC
fixed-dose combination (of medicines)
GDF
Global Drug Facility
GDG
Guideline Development Group
GRADE
Grading of Recommendations Assessment, Development and Evaluation
HBV
hepatitis B virus
HCV
hepatitis C virus
HCW
health care worker
HIV
human immunodeficiency virus
HR
isoniazid–rifampicin
HRZE
isoniazid–rifampicin–ethambutol–pyrazinamide
(H)RZE
(isoniazid optional)–rifampicin–ethambutol–pyrazinamide
Hr-TB
rifampicin-susceptible, isoniazid-resistant tuberculosis
IMCI
integrated management of childhood illness
IPD
individual patient data (or dataset)
IRIS
immune reconstitution inflammatory syndrome
IV
intravenous
LC-aNAAT
low-complexity automated NAAT
LC-mNAAT
low-complexity manual NAAT
LFT
liver function test
LPA
line probe assay
LTFU
loss to follow-up
MC-aNAAT
moderate-complexity automated NAAT
MC-mNAAT
moderate-complexity manual NAAT
MDR-TB
multidrug-resistant tuberculosis
MDR/RR-TB
multidrug- or rifampicin-resistant tuberculosis
MGIT
mycobacterial growth indicator tube
MIC
minimum inhibitory concentration
mWRD
molecular WHO-recommended rapid diagnostic
NAAT
nucleic acid amplification test
NGS
next-generation sequencing
NTM
non-tuberculosis mycobacteria
NTP
national tuberculosis programme
PHC
primary health care
PLHIV
people living with HIV
pre-XDR-TB
pre-extensively drug-resistant tuberculosis
PTB
pulmonary tuberculosis
RCT
randomized controlled trial
rGLC
regional Green Light Committee
RR-TB
rifampicin-resistant tuberculosis
SAM
severe acute malnutrition
SDG
Sustainable Development Goal
SMS
short message service or text message
SoC
standard of care
TB
tuberculosis
TDM
therapeutic drug monitoring
TPT
tuberculosis preventive treatment
VST
video-supported treatment
WHO
World Health Organization
WHO/GTB
Global Programme on Tuberculosis & Lung Health of the World Health Organization
XDR-TB
extensively drug-resistant tuberculosis
TB medicines
Am
amikacin
B or Bdq
bedaquiline
C or Cfz
clofazimine
Cs
cycloserine
D or Dlm
delamanid
E
ethambutol
Eto
ethionamide
FQ
fluoroquinolone
H
isoniazid
Hh
isoniazid high dose
Ipm-Cln
imipenem–cilastatin
L or Lzd
linezolid
Lfx
levofloxacin
M or Mfx
moxifloxacin
Mpm
meropenem
P or Rpt
rifapentine
Pa
pretomanid
PAS
p-aminosalicylic acid
Pto
prothionamide
R
rifampicin
S
streptomycin
Trd
terizidone
Z or PZA
pyrazinamide